Javid H, Rahimian R, Salimi M, Haghani-Samani E, Farhadi M, Torkaman-Boutorabi A
Mol Biol Rep. 2024; 51(1):768.
PMID: 38884894
DOI: 10.1007/s11033-024-09673-5.
Nongthombam P, Haobam R
Mol Biol Rep. 2024; 51(1):510.
PMID: 38622307
DOI: 10.1007/s11033-024-09484-8.
Tesoro C, Ciriello R, Lelario F, Di Capua A, Pascale R, Bianco G
Molecules. 2022; 27(21).
PMID: 36364292
PMC: 9654252.
DOI: 10.3390/molecules27217468.
Tiwari P, Chaudhary M, Pal R, Kartik S, Nath R
Ann Neurosci. 2022; 28(3-4):137-149.
PMID: 35341236
PMC: 8948331.
DOI: 10.1177/09727531211051976.
Hormann P, Delcambre S, Hanke J, Geffers R, Leist M, Hiller K
Cell Death Discov. 2021; 7(1):151.
PMID: 34226525
PMC: 8257685.
DOI: 10.1038/s41420-021-00547-4.
A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation.
Steele J, Strange N, Rodgers K, Padula M
Proteomes. 2021; 9(2).
PMID: 34073856
PMC: 8162537.
DOI: 10.3390/proteomes9020024.
Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson's disease.
Zhong J, Dong W, Qin Y, Xie J, Xiao J, Xu J
Br J Pharmacol. 2020; 177(10):2333-2350.
PMID: 31972868
PMC: 7174887.
DOI: 10.1111/bph.14983.
Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of 3-Hydroxymorphinan.
Li Z, Bao X, Bai X, Zhang G, Wang J, Zhu M
Sci Rep. 2019; 9(1):2247.
PMID: 30783196
PMC: 6381151.
DOI: 10.1038/s41598-019-38911-1.
Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
Zhang F, He Y, Zheng Y, Zhang W, Wang Q, Jia Y
CNS Neurosci Ther. 2014; 20(12):1036-44.
PMID: 25399812
PMC: 6493059.
DOI: 10.1111/cns.12340.
Functional studies of tyrosine hydroxylase missense variants reveal distinct patterns of molecular defects in Dopa-responsive dystonia.
Fossbakk A, Kleppe R, Knappskog P, Martinez A, Haavik J
Hum Mutat. 2014; 35(7):880-90.
PMID: 24753243
PMC: 4312968.
DOI: 10.1002/humu.22565.
Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder.
Alexander G
Dialogues Clin Neurosci. 2011; 6(3):259-80.
PMID: 22033559
PMC: 3181806.
No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study.
Gnana Oli R, Fazeli G, Kuhn W, Walitza S, Gerlach M, Stopper H
J Neural Transm (Vienna). 2010; 117(6):737-46.
PMID: 20401731
DOI: 10.1007/s00702-010-0401-z.
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease.
Lee M, Tazzari V, Giustarini D, Rossi R, Sparatore A, Del Soldato P
J Biol Chem. 2010; 285(23):17318-28.
PMID: 20368333
PMC: 2878495.
DOI: 10.1074/jbc.M110.115261.
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Nowak P, Kostrzewa R, Skaba D, Kostrzewa R
Neurotox Res. 2009; 17(3):299-304.
PMID: 19760476
DOI: 10.1007/s12640-009-9105-2.
Microglial responses to dopamine in a cell culture model of Parkinson's disease.
Mastroeni D, Grover A, Leonard B, Joyce J, Coleman P, Kozik B
Neurobiol Aging. 2008; 30(11):1805-17.
PMID: 18325635
PMC: 2762863.
DOI: 10.1016/j.neurobiolaging.2008.01.001.
Sources and targets of reactive oxygen species in synaptic plasticity and memory.
Kishida K, Klann E
Antioxid Redox Signal. 2006; 9(2):233-44.
PMID: 17115936
PMC: 3544198.
DOI: 10.1089/ars.2007.9.ft-8.
Rivastigmine for dementia associated with Parkinson's disease.
Morgan J, Sethi K
Curr Neurol Neurosci Rep. 2005; 5(4):263-5.
PMID: 15987609
DOI: 10.1007/s11910-005-0070-8.
Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells.
Liu W, Chen Y, Li B, Lu G, Chen S
Neurochem Res. 2005; 29(12):2207-14.
PMID: 15672541
DOI: 10.1007/s11064-004-7027-1.
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.
Bustamante D, Bustamante L, Segura-Aguilar J, Goiny M, Herrera-Marschitz M
Neurotox Res. 2004; 5(8):569-77.
PMID: 15111234
DOI: 10.1007/BF03033177.
Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.
Asanuma M, Miyazaki I, Ogawa N
Neurotox Res. 2003; 5(3):165-76.
PMID: 12835121
DOI: 10.1007/BF03033137.